Inside the UAE cancer pilot
BioTwin runs its first clinical cancer pilot in the United Arab Emirates, with Cleveland Clinic Abu Dhabi. Here is what it delivers today and what it does not.
The partnership
BioTwin partners with Cleveland Clinic Abu Dhabi to deliver cancer screening results for two specific cancers today: breast cancer and colorectal cancer. Patients are referred by their physicians at the clinic, not the other way around. Results are returned to the referring physician, who interprets them in the context of the patient's full medical record. BioTwin does not deliver clinical findings directly to patients in the pilot. The programme operates under the regulatory framework of the United Arab Emirates.
Why breast and colorectal first
Both cancers have well understood Bio-Signatures. BioTwin's technology is being studied for regulated clinical decision assistance. Starting with two cancers where the science is strongest lets BioTwin validate its virtual twin under clinical supervision before expanding. Research continues on other cancers in parallel, but the pilot stays deliberately narrow so that every result delivered to a physician is backed by the strongest available evidence.
What this means for BioTwin customers in the US and Canada
Clinical availability remains jurisdiction-specific: BioTwin's cancer screening decision-assistance pathway is available only through participating physicians in authorized UAE clinical settings. Canada and U.S. clinical availability is pending Health Canada and FDA review. The UAE pilot is a pilot, not a direct-to-consumer product line. As the research matures and regulators in other jurisdictions approve new uses, additional pilots will follow the same physician-referred path first.